EUVIMEDEUVIMED entdecken
Crossref

Project Twenty21 Australia: Results of a prospective observational study of patients prescribed medicinal cannabis for chronic pain, anxiety and post-traumatic stress disorder

Kylie O’Brien, Justin Beilby, Michael Lynskey, Michael Barnes, Anne Schlag, David Nutt

Drug Science, Policy and Law · 2026-08 · 12

DOI: 10.1177/20503245261475953 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Science, Policy and Law, online erschienen am 10.08.2026. Verfasst von Kylie O’Brien und 5 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Medicinal cannabis (MC) became legalised in Australia in 2016, yet relatively little is known about its longer-term effectiveness within the Australian context.

Methods

P2021 Australia was a prospective observational cohort study that collected data on patients prescribed MC (from as Product Formulary) for four conditions: chronic pain, anxiety, post-traumatic stress disorder (PTSD) and multiple sclerosis (MS) via validated questionnaires (baseline then 3-monthly for up to 12 months).

Results

At study end, a total of 522 patients had enrolled: 221 (42.3%) reported their primary complaint was chronic pain, 222 (42.5%) anxiety, 53 (10.2%) PTSD and 26 (5%) other conditions. Three-month data for chronic pain, anxiety and PTSD indicate MC is effective at reducing primary symptoms as well as improving quality of life (QoL), sleep, mood/depression and perceived overall health (insufficient data for MS). In chronic pain patients, effect sizes (Cohen's d ) at 3 months were 0.75 for pain severity and 0.8 for pain interference (BPI questionnaire), for anxiety patients, 1.34(GAD-7 questionnaire) and for PTSD patients 1.44 (PTSD Checklist-Civilian Version), and there were also significant improvements across other measures, including QoL, perceived overall health, mood/depression and sleep, with effect sizes ranging from 0.54 to 1.15. Twelve-month data for chronic pain and anxiety patients indicates that MC use is associated with improvements in primary symptoms, QoL, perceived overall health, mood/depression and sleep quality (insufficient data for PTSD and MS).

Conclusion

MC may be a useful treatment option for conditions, including chronic pain, anxiety and PTSD, where other treatments have not been successful.

Zitieren

APA

O’Brien, K., Beilby, J., Lynskey, M., Barnes, M., Schlag, A., & Nutt, D. (2026). Project Twenty21 Australia: Results of a prospective observational study of patients prescribed medicinal cannabis for chronic pain, anxiety and post-traumatic stress disorder. Drug Science, Policy and Law, 12. https://doi.org/10.1177/20503245261475953

Vancouver

O’Brien K, Beilby J, Lynskey M, Barnes M, Schlag A, Nutt D. Project Twenty21 Australia: Results of a prospective observational study of patients prescribed medicinal cannabis for chronic pain, anxiety and post-traumatic stress disorder. Drug Science, Policy and Law. 2026;12. doi:10.1177/20503245261475953

BibTeX
@article{OBrien2026,
  author = {O’Brien, Kylie and Beilby, Justin and Lynskey, Michael and Barnes, Michael and Schlag, Anne and Nutt, David},
  title = {Project Twenty21 Australia: Results of a prospective observational study of patients prescribed medicinal cannabis for chronic pain, anxiety and post-traumatic stress disorder},
  journal = {Drug Science, Policy and Law},
  year = {2026},
  volume = {12},
  doi = {10.1177/20503245261475953}
}
Kostenlos starten →